Key facts

Active substance
  • emtricitabine
  • rilpivirine
  • tenofovir alafenamide
Therapeutic area
Infectious diseases
Decision number
PIP number
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral formulation
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Gilead Sciences International Ltd 
United Kingdom
Tel. +44 (0)1223 897300 
Fax +44 (0)1223 897284
E-mail: regulatory.pip@gilead.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)


How useful was this page?

Add your rating